
Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the &#34;Company&#34;), the world&#39;s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February

<p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Cryo-Cell International, Inc. (NYSE American LLC: CCEL )</b> (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Financial Results</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Revenue</i></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million in processing and storage fee revenue, $36,000 in product revenue and approximately $1,400 in public banking revenue compared to $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately $82,000 in public banking revenue for the first quarter of fiscal 2025.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Net Income</i></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company reported net income of approximately $47,000 or $0.01 per basic and diluted common share for the three months ended February 28, 2026, compared to net income of approximately $283,000, or $0.03 per basic and diluted common share for the same period in 2025.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">About Cryo-Cell International, Inc.</i></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. ‎ The Company currently stores over 250,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and possibly other members of their families. In addition to its private bank, Cryo-Cell ‎International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell's ‎public bank has provided cord blood for more than 700 transplants and operates a cord ‎blood donation site at one of the country's most prominent hospitals, Cedars–Sinai Hospital in ‎Los Angeles. Cryo-Cell's facility is FDA registered, cGMP-/cGTP-‎compliant and licensed in all states requiring licensure. Besides being AABB accredited as a ‎cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ‎receive FACT accreditation for adhering to the most stringent cord blood quality standards ‎set by any internationally recognized, independent accrediting organization. Cryo-Cell has ‎the exclusive rights ‎to PrepaCyte-CB, the industry's most advanced cord blood processing ‎technology.‎

</p><p xmlns="http://www.w3.org/1999/xhtml">
Cryo-Cell's mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by terminology such as "will," "may," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential" or "continue" or the negative of these terms or other comparable terminology. Generally, the words "anticipate," "believe," "continue," "expect," "intend," "estimate," "project," "plan" and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.

</p><p xmlns="http://www.w3.org/1999/xhtml">
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company's global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the success of the Company's initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company's ability to minimize future costs to the Company related to R&amp;D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company's umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company's Form 10-K filed on February 27, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260414824820r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260414824820/en/" rel="nofollow">https://www.businesswire.com/news/home/20260414824820/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Irene Smith
<br xmlns="http://www.w3.org/1999/xhtml"></br>813-749-2102
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:Ismith@cryo-cell.com" shape="rect">Ismith@cryo-cell.com</a>

</p>

CCEL

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

Cryo-Cell Reports Declining Revenue and Net Income in Q1 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the &amp;#34;Company&amp;#34;), the world&amp;#39;s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cryo-Cell International (CCEL) reported Q1 2026 revenues of $7.68 million, down from $7.97 million in the prior year, alongside a significant drop in net income. With a focus on global expansion and biopharmaceutical initiatives, the company faces risks that may impact its operational growth.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CCEL&#039;s Q1 2026 revenue decreased to $7.68 million from $7.97 million.</li><li>Net income fell significantly to $47,000 compared to $283,000 last year.</li><li>Company focuses on expanding global initiatives and biopharmaceutical manufacturing.</li><li>CCEL holds exclusive rights to advanced cord blood processing technology.</li><li>Forward-looking statements indicate potential risks in revenue and operational growth.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Duke University (N/A)</strong>: Partner in CCEL’s public banking program, enhancing credibility.</li><li><strong>Cedars-Sinai Hospital (N/A)</strong>: Location of CCEL&#039;s donation site, pivotal for public banking initiatives.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it primarily discusses CCEL&#039;s financial performance and strategic directions, which are critical for assessing company viability.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Declining revenue trends could lead to investor caution in CCEL shares.</li><li>Significantly reduced net income may affect market confidence and future valuation.</li><li>Operational risks from global expansion could hinder long-term growth prospects.</li><li>Exclusive rights to processing technology could offer competitive advantages if utilized effectively.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q1 2026 revenue: $7.68 million, compared to $7.97 million for Q1 2025.</li><li>Net income dropped to $47,000, down from $283,000 year-over-year.</li><li>Company stored over 250,000 cord blood specimens.</li><li>Public bank program contributed to 700 successful transplants at major hospitals.</li><li>Includes advanced processing technology exclusive to Cryo-Cell.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CCEL may experience short-term price pressure due to declining revenue and profitability.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Cryo-Cell International, Inc. (NYSE American LLC: CCEL )</b> (the "Company"), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Financial Results</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Revenue</i></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first quarter of fiscal 2025. The revenues for the first quarter of fiscal 2026 consisted of $7.64 million in processing and storage fee revenue, $36,000 in product revenue and approximately $1,400 in public banking revenue compared to $7.87 million in processing and storage fee revenue, $21,000 in product revenue and approximately $82,000 in public banking revenue for the first quarter of fiscal 2025.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Net Income</i></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company reported net income of approximately $47,000 or $0.01 per basic and diluted common share for the three months ended February 28, 2026, compared to net income of approximately $283,000, or $0.03 per basic and diluted common share for the same period in 2025.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">About Cryo-Cell International, Inc.</i></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. ‎ The Company currently stores over 250,000 cord blood and cord tissue specimens for the exclusive benefit of newborn babies and possibly other members of their families. In addition to its private bank, Cryo-Cell ‎International, Inc. has a public banking program in partnership with Duke University. Cryo-Cell's ‎public bank has provided cord blood for more than 700 transplants and operates a cord ‎blood donation site at one of the country's most prominent hospitals, Cedars–Sinai Hospital in ‎Los Angeles. Cryo-Cell's facility is FDA registered, cGMP-/cGTP-‎compliant and licensed in all states requiring licensure. Besides being AABB accredited as a ‎cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ‎receive FACT accreditation for adhering to the most stringent cord blood quality standards ‎set by any internationally recognized, independent accrediting organization. Cryo-Cell has ‎the exclusive rights ‎to PrepaCyte-CB, the industry's most advanced cord blood processing ‎technology.‎

</p><p xmlns="http://www.w3.org/1999/xhtml">
Cryo-Cell's mission is to provide premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, you can identify forward-looking statements by terminology such as "will," "may," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential" or "continue" or the negative of these terms or other comparable terminology. Generally, the words "anticipate," "believe," "continue," "expect," "intend," "estimate," "project," "plan" and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.

</p><p xmlns="http://www.w3.org/1999/xhtml">
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company's global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company's actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company's future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company's business, the success of the Company's initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company's ability to minimize future costs to the Company related to R&amp;D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company's umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company's Form 10-K filed on February 27, 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260414824820r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260414824820/en/" rel="nofollow">https://www.businesswire.com/news/home/20260414824820/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
Irene Smith
<br xmlns="http://www.w3.org/1999/xhtml"></br>813-749-2102
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:Ismith@cryo-cell.com" shape="rect">Ismith@cryo-cell.com</a>

</p>

Cryo-Cell International (CCEL) reported Q1 2026 revenues of $7.68 million, down from $7.97 million in the prior year, alongside a significant drop in net income. With a focus on global expansion and biopharmaceutical initiatives, the company faces risks that may impact its operational growth.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News